Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure

Ulrich P. Jorde, Timothy Vittorio, Stuart D. Katz, Paolo C. Colombo, Farhana Latif, Thierry H. Le Jemtel

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Background - Plasma aldosterone levels are elevated in patients with chronic heart failure (CHF) taking angiotensin-converting enzyme (ACE) inhibitors. Elevated aldosterone levels may reflect incomplete inhibition of the vascular converting enzyme during long-term ACE inhibition. We simultaneously measured plasma aldosterone levels and the degree of inhibition of the vascular converting enzyme in patients with CHF. Methods and Results - Thirty-four subjects with CHF receiving the maximum recommended doses of ACE inhibitors for a duration of 3 to 105 months were studied. The pressor response to exogenous angiotensin I (AI) was measured and normalized for the pressor response to angiotensin II (AII) to assess inhibition of the vascular converting enzyme (AII/AI ratio). Aldosterone levels were determined by solid-phase radioimmunoassay. Eleven of the 34 subjects had plasma aldosterone levels above the upper limit of normal, ie, > 15.0 ng/dL. Seven of these 11 subjects (64%) had an AII/AI ratio ≤0.05, indicating complete inhibition of the vascular converting enzyme. In the entire cohort, the AII/AI ratio did not correlate with the duration of ACE inhibitor therapy. Conclusions - Plasma aldosterone levels are elevated in patients with CHF during long-term ACE inhibitor therapy despite complete inhibition of the vascular converting enzyme. Complete inhibition of the vascular converting enzyme does not obviate the need for aldosterone receptor blockade in patients with CHF.

Original languageEnglish (US)
Pages (from-to)1055-1057
Number of pages3
JournalCirculation
Volume106
Issue number9
DOIs
StatePublished - Aug 27 2002

Fingerprint

Peptidyl-Dipeptidase A
Aldosterone
Blood Vessels
Angiotensin I
Heart Failure
Angiotensin-Converting Enzyme Inhibitors
Angiotensin II
Enzyme Therapy
Enzymes
Mineralocorticoid Receptors
Radioimmunoassay

Keywords

  • Aldosterone
  • Angiotensin
  • Heart failure

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. / Jorde, Ulrich P.; Vittorio, Timothy; Katz, Stuart D.; Colombo, Paolo C.; Latif, Farhana; Le Jemtel, Thierry H.

In: Circulation, Vol. 106, No. 9, 27.08.2002, p. 1055-1057.

Research output: Contribution to journalArticle

Jorde, Ulrich P. ; Vittorio, Timothy ; Katz, Stuart D. ; Colombo, Paolo C. ; Latif, Farhana ; Le Jemtel, Thierry H. / Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. In: Circulation. 2002 ; Vol. 106, No. 9. pp. 1055-1057.
@article{fccbc4c710894faf8d01e266efdb4948,
title = "Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure",
abstract = "Background - Plasma aldosterone levels are elevated in patients with chronic heart failure (CHF) taking angiotensin-converting enzyme (ACE) inhibitors. Elevated aldosterone levels may reflect incomplete inhibition of the vascular converting enzyme during long-term ACE inhibition. We simultaneously measured plasma aldosterone levels and the degree of inhibition of the vascular converting enzyme in patients with CHF. Methods and Results - Thirty-four subjects with CHF receiving the maximum recommended doses of ACE inhibitors for a duration of 3 to 105 months were studied. The pressor response to exogenous angiotensin I (AI) was measured and normalized for the pressor response to angiotensin II (AII) to assess inhibition of the vascular converting enzyme (AII/AI ratio). Aldosterone levels were determined by solid-phase radioimmunoassay. Eleven of the 34 subjects had plasma aldosterone levels above the upper limit of normal, ie, > 15.0 ng/dL. Seven of these 11 subjects (64{\%}) had an AII/AI ratio ≤0.05, indicating complete inhibition of the vascular converting enzyme. In the entire cohort, the AII/AI ratio did not correlate with the duration of ACE inhibitor therapy. Conclusions - Plasma aldosterone levels are elevated in patients with CHF during long-term ACE inhibitor therapy despite complete inhibition of the vascular converting enzyme. Complete inhibition of the vascular converting enzyme does not obviate the need for aldosterone receptor blockade in patients with CHF.",
keywords = "Aldosterone, Angiotensin, Heart failure",
author = "Jorde, {Ulrich P.} and Timothy Vittorio and Katz, {Stuart D.} and Colombo, {Paolo C.} and Farhana Latif and {Le Jemtel}, {Thierry H.}",
year = "2002",
month = "8",
day = "27",
doi = "10.1161/01.CIR.0000030935.89559.04",
language = "English (US)",
volume = "106",
pages = "1055--1057",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure

AU - Jorde, Ulrich P.

AU - Vittorio, Timothy

AU - Katz, Stuart D.

AU - Colombo, Paolo C.

AU - Latif, Farhana

AU - Le Jemtel, Thierry H.

PY - 2002/8/27

Y1 - 2002/8/27

N2 - Background - Plasma aldosterone levels are elevated in patients with chronic heart failure (CHF) taking angiotensin-converting enzyme (ACE) inhibitors. Elevated aldosterone levels may reflect incomplete inhibition of the vascular converting enzyme during long-term ACE inhibition. We simultaneously measured plasma aldosterone levels and the degree of inhibition of the vascular converting enzyme in patients with CHF. Methods and Results - Thirty-four subjects with CHF receiving the maximum recommended doses of ACE inhibitors for a duration of 3 to 105 months were studied. The pressor response to exogenous angiotensin I (AI) was measured and normalized for the pressor response to angiotensin II (AII) to assess inhibition of the vascular converting enzyme (AII/AI ratio). Aldosterone levels were determined by solid-phase radioimmunoassay. Eleven of the 34 subjects had plasma aldosterone levels above the upper limit of normal, ie, > 15.0 ng/dL. Seven of these 11 subjects (64%) had an AII/AI ratio ≤0.05, indicating complete inhibition of the vascular converting enzyme. In the entire cohort, the AII/AI ratio did not correlate with the duration of ACE inhibitor therapy. Conclusions - Plasma aldosterone levels are elevated in patients with CHF during long-term ACE inhibitor therapy despite complete inhibition of the vascular converting enzyme. Complete inhibition of the vascular converting enzyme does not obviate the need for aldosterone receptor blockade in patients with CHF.

AB - Background - Plasma aldosterone levels are elevated in patients with chronic heart failure (CHF) taking angiotensin-converting enzyme (ACE) inhibitors. Elevated aldosterone levels may reflect incomplete inhibition of the vascular converting enzyme during long-term ACE inhibition. We simultaneously measured plasma aldosterone levels and the degree of inhibition of the vascular converting enzyme in patients with CHF. Methods and Results - Thirty-four subjects with CHF receiving the maximum recommended doses of ACE inhibitors for a duration of 3 to 105 months were studied. The pressor response to exogenous angiotensin I (AI) was measured and normalized for the pressor response to angiotensin II (AII) to assess inhibition of the vascular converting enzyme (AII/AI ratio). Aldosterone levels were determined by solid-phase radioimmunoassay. Eleven of the 34 subjects had plasma aldosterone levels above the upper limit of normal, ie, > 15.0 ng/dL. Seven of these 11 subjects (64%) had an AII/AI ratio ≤0.05, indicating complete inhibition of the vascular converting enzyme. In the entire cohort, the AII/AI ratio did not correlate with the duration of ACE inhibitor therapy. Conclusions - Plasma aldosterone levels are elevated in patients with CHF during long-term ACE inhibitor therapy despite complete inhibition of the vascular converting enzyme. Complete inhibition of the vascular converting enzyme does not obviate the need for aldosterone receptor blockade in patients with CHF.

KW - Aldosterone

KW - Angiotensin

KW - Heart failure

UR - http://www.scopus.com/inward/record.url?scp=0037183651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037183651&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000030935.89559.04

DO - 10.1161/01.CIR.0000030935.89559.04

M3 - Article

C2 - 12196328

AN - SCOPUS:0037183651

VL - 106

SP - 1055

EP - 1057

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 9

ER -